Ventripoint's VMS+ 4.0 Submitted for Approval in China via Green Channel

Ventripoint Diagnostics Ltd. (TSX-V:VPT, OTC:VPTDF) has achieved a critical regulatory milestone as its strategic partner, Lishman Global Inc., formally submitted the VMS+™ 4.0 system to China’s National Medical Products Administration (NMPA). Importantly, the submission qualifies for the NMPA’s “green channel” pathway, an expedited review process for innovative medical technologies addressing significant clinical needs. This designation is expected to accelerate approval and market access in China.

China represents a massive opportunity in cardiology, with cardiovascular disease as the leading cause of death and an estimated 330 million patients. Echocardiography is widely used due to its cost-effectiveness, but variability in interpretation and limited access to MRI create a need for AI-driven tools. Ventripoint’s VMS+™ 4.0 addresses this by providing MRI-equivalent volumetric measurements using standard 2D echocardiography, powered by Knowledge Based Reconstruction technology. The platform enables accurate assessment of all four heart chambers, supporting diagnosis of congenital heart defects, heart failure, pulmonary hypertension, cardiotoxicity, and valvular disease.

Paul Gibson, CTO of Lishman Global, said, “Qualification for the NMPA’s green channel underscores the clinical relevance and innovation of VMS+™ 4.0.” Hugh MacNaught, CEO of Ventripoint, added, “China is one of the most important cardiac care markets. With an expedited review pathway, we are well positioned to bring VMS+™ 4.0 to clinicians and patients more quickly.” The company will provide updates as the review progresses. The original release can be viewed on NEWMEDIAWIRE.